Vaxart, INC DEF 14A proxy statements

Vaxart, Inc. has adjourned its 2025 special meeting of stockholders to September 19, 2025, to allow more time for consideration of recent board and governance changes, and potential future disclosures.

Vaxart management strongly urges stockholders to approve a reverse stock split to regain NASDAQ compliance, citing benefits for capital access, visibility, and investor protection.

Vaxart, Inc. announced a virtual fireside chat to discuss its reverse stock split proposal, which has received support from ISS and Glass Lewis, aimed at regaining Nasdaq compliance.

Vaxart's CEO urges stockholders to approve a reverse stock split to regain Nasdaq listing, citing benefits for investor access and financing, despite a recent Stop Work Order on its COVID-19 vaccine trial.

Vaxart, Inc. is seeking stockholder approval for a reverse stock split, ranging from 1-for-5 to 1-for-20, aimed at increasing its share price to meet Nasdaq's minimum bid requirement and avoid delisting.

Vaxart's Founder and CSO, Dr. Sean Tucker, released a video urging stockholders to vote for a reverse stock split to regain compliance with Nasdaq's minimum bid price rule.

Vaxart, Inc. is urging stockholders to vote for a reverse stock split by June 1, 2025, to regain Nasdaq compliance and avoid delisting, while addressing frequently asked questions regarding capital raises, program funding, and market speculation.

Vaxart is seeking stockholder approval for a reverse stock split to maintain its Nasdaq listing and proposes reducing authorized shares at a future meeting.

Vaxart's board has decided to limit the reverse stock split ratio and plans a subsequent reduction in authorized shares, contingent on stockholder approval.

Vaxart is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and avoid delisting.

Vaxart is seeking stockholder approval for a reverse stock split to maintain its Nasdaq listing while advancing its COVID-19 and norovirus vaccine programs.

Vaxart urges stockholders to approve a reverse stock split proposal to avoid Nasdaq delisting and potentially enhance financial flexibility.

Vaxart, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) regarding its upcoming shareholder meeting.

Vaxart is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing and elect six directors at the upcoming annual meeting.

Vaxart, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) regarding its upcoming shareholder meeting.

Vaxart is asking stockholders to approve an increase in authorized shares and amendments to its equity incentive plans at the upcoming annual meeting.